Current hair regeneration methods show promise but face challenges in maintaining cell effectiveness and creating the right environment for hair growth.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymalstemcells and shows promise in treating hair loss, unlike Pelage's PP405.
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hairfollicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stemcells for potential hair growth solutions.
Pelage is developing a topical hairfolliclestem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
Hairfolliclestemcells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hairfollicles, potentially offering a long-term solution, though not a permanent cure.